Table of Contents
Amgen reveals the price of EVENITY
Amgen has set the price of its newly launched Osteoporosis drug Romosozumab (Evenity). Worth USD 21,900 per annum or USD 1,825 a month, the bone-building drug was approved by the FDA recently for the treatment of Osteoporosis in postmenopausal women and now will be available in the U.S. The price of Evenity is 34-74% lower than the cost of other available drugs like Tymlos of Radius Health and Forteo of Eli Lilly.
Bardy Diagnostics raises USD 35.5 Million
Bardy Diagnostics, an American based leading provider of ambulatory cardiac monitoring technologies has raised USD 35.5 million. The Series B funding was led by River Cities Capital Funds. The funds will help Bardy to boost the growth of its innovative cardiac monitoring platform, intelligence and visualization technologies, expansion of its sales and monitoring services.
Kiadis to Acquire CytoSen Therapeutics for 1.94 million shares
Kiadis Pharma NV, a Dutch biotech is all set to buy CytoSen Therapeutics, which has been working on NK cell platform to enable NK cell therapy with broad anti-cancer potential. Kiadis is focused on developing ATIR101 a drug ought to bring positive results in treating Cancer specifically for patients undergoing haploidentical hematopoietic stem cell transplants (HSCT). The joint deal will provide promising treatment options by combining T-cell therapies with NK cells.
Insitro lands a deal with Gilead worth USD 15 million
Insitro, a California-based drug discovery startup has inked a three-year pact with the pharma giant Gilead. The collaboration will require Gilead to fund Insitro to help the latter to find medicines to treat liver disease, and NonAlcoholic Steatohepatitis (NASH). Insitro, with all the financial help, will be able to improve drug discovery and regulate the enormous data with the use of its advanced computing tools.